Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zabilugene Almadenorepvec · VCN-01

Oncolytic virus (Adenoviral vector) · Kills target cells, directed at hyaluronic acid · developed by Theriva Biologics SL

Phase 1/2 Most advanced trial
TOVX Developer
2 Registered trials

What is Zabilugene Almadenorepvec?

Zabilugene almadenorepvec (VCN-01) is an oncolytic, replication-competent adenovirus encoding the human PH20 hyaluronidase. After intratumoral or intravenous administration it replicates in tumor cells, causing cell death and spreading to adjacent tumor cells, while the hyaluronidase degrades tumor hyaluronic acid. It is studied in pancreatic cancer and serous ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VCN-01
Drug type
Oncolytic virus (Adenoviral vector)
Targets
hyaluronic acid (secondary target)
Mechanism
Kills target cells, directed at hyaluronic acid
Pathways
hyaluronic acid degradation, reduction of interstitial fluid pressure, oncolytic virus-induced cell death
Therapy area
Oncology
Developer
Theriva Biologics SL (TOVX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
3HBM7CA87P

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07701486 Phase 1/2 Pancreas Cancer, Metastatic Recruiting TOVX
NCT05057715 Phase 1 Pancreatic Cancer Terminated TOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ductal Adenocarcinoma of the PancreasPancreas Cancer, MetastaticPancreas Cancer, Stage IVPancreatic CancerSerous Ovarian Cancer

More from Theriva Biologics SL

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TOVX page.

Follow TOVX, the company behind Zabilugene Almadenorepvec

See TOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TOVX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.